Rover to acquire Australia-based pet sitting marketplace Mad Paws
Seattle-based Rover is set to acquire Mad Paws, a pet-sitting company that describes itself as Australia's leading online pet ecosystem.
The deal is valued at about $40 million, according to a press release.
Mad Paws facilitated more than 400,000 transactions in 2024 and has more than 300,00 active pet parents on its platform. The Sydney-based company, which went public in 2021 and will continue to operate as a standalone brand, has more than 300 employees.
Rover intends to acquire Mad Paws' online marketplace business but not its e-commerce division.
Rover bills itself as the world's largest network of pet sitters and dog walkers. The company was acquired by Blackstone last year in a $2.3 billion private equity deal.
'This transaction marks a pivotal moment for Rover's international growth and underscores our global leadership in the pet care space,' Rover CEO Brent Turner said in a statement.
Rover has previously focused on expansion throughout North America and Europe, including the acquisitions of European companies Cat In A Flat (2024) and Gudog (2025).
Turner was recently appointed CEO, replacing co-founder Aaron Easterly.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Acadian Asset Management Inc. Reports Financial and Operating Results for the Second Quarter Ended June 30, 2025
BOSTON, July 31, 2025--(BUSINESS WIRE)--Acadian Asset Management Inc. (NYSE: AAMI) today announced its results for the second quarter ended June 30, 2025. Acadian Asset Management Inc.'s earnings presentation is available at: The Company will hold a conference call and simultaneous webcast to discuss the results at 11:00 a.m. Eastern Time today. To listen to the call or view the webcast, participants should: Dial-in Toll Free Dial-in Number: (800) 715-9871 International Dial-in Number: (646) 307-1963 Conference ID: 9046067 Visit for the webcast link (register ahead of time or join immediately prior to the call). A replay of the call will be available beginning approximately one hour after its conclusion either on Acadian Asset Management Inc.'s website, at or by: Dial-in Replay Toll Free Dial-in Number: (800) 770-2030 International Dial-in Number: (609) 800-9909 Conference ID: 9046067 About Acadian Asset Management Inc. Acadian Asset Management Inc. is the NYSE listed holding company of Acadian Asset Management LLC, with approximately $151 billion of assets under management as of June 30, 2025. Acadian offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives. For more information, please visit the Company's website at Information that may be important to investors will be routinely posted on our website. View source version on Contacts Investor Relationsir@ (617) 369-7300 Sign in to access your portfolio
Yahoo
11 minutes ago
- Yahoo
Cora Restaurants Enhances the Guest Experience Offering Online Reservations Powered by Libro
MONTREAL, July 31, 2025--(BUSINESS WIRE)--Cora restaurants, a Canadian leader in the breakfast scene for over 35 years, is proud to announce their partnership with Libro to offer an online reservation platform. Starting today, guests can now book their table in advance—quickly and easily. This move represents another step forward in enhancing the Cora customer experience, catering to today's demand for convenience, flexibility, and efficiency. The reservation platform is now accessible via the Cora website and directly through Google or Facebook. Guests can choose their preferred Cora location and time slot—all in just a few clicks. "We know our guests lead busy lives. With online reservations, they can now plan their visit with peace of mind, knowing their table is waiting for them when they arrive," says François Lamontagne, Vice President of Finance and Corporate Operations at Cora. The nationwide launch of the reservation platform is a strategic response to evolving consumer habits. Today's guests expect the same digital conveniences in dining as they do when booking a hotel or ordering groceries online. Libro's reservation platform reduces wait times during peak hours, including weekends, holidays, and busy mornings—making visits to Cora more enjoyable for all. "Cora is a Canadian icon, and we're thrilled to support their vision of exceptional hospitality," says Lorne Schwartz, President at Libro. About Franchises Cora Franchises Cora Inc. has over 100 restaurants from coast to coast, making it the largest breakfast restaurant chain in Canada. The company has been in business for more than thirty-five years. To learn more, visit About Libro Libro is one of North America's leading online guest experience solutions providing restaurants with an affordable, fully branded solution to fill tables, manage reservations, reduce no-shows, engage customers, and elevate the overall guest experience. For more information, visit View source version on Contacts Abby Chitester, VP Marketing at Libro abby@
Yahoo
11 minutes ago
- Yahoo
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO
This Offering Will Not Dilute Quantum BioPharma Shareholders TORONTO, July 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ('Quantum BioPharma'), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced that Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzdTM – the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms – today announced the launch of its previously announced Regulation D 506(c) offering to raise up to US$5.0 million to fund growth and establish a path to a possible initial public offering. This will not impact or dilute Quantum BioPharma shareholders. Quantum BioPharma maintains an anti-dilution provision which ensures its ownership in Unbuzzd Wellness Inc. is 25% until unbuzzd reaches $1,000,000,000 (One Billion US Dollars) in valuation. Once Unbuzzd Wellness Inc. goes public, Quantum BioPharma will be able to access non-dilutive capital through its ownership. Unbuzzd has partnered with MZ Digital, a global leader in marketing, and Dealmaker, a leading online platform for raising capital to conduct the capital raise campaign. The Regulation D offering allows Unbuzzd to raise capital by selling and issuing securities to accredited investors without a cap on the amount raised. Investments can be made with traditional payments or with cryptocurrency payments: the latter through ALT5 Pay's digital payments platform. To learn more about the offering and invest, visit this link Unbuzzd Invest. John Duffy, CEO of Unbuzzd Wellness, stated, "This capital raise allows us to introduce investors to a new era in functional beverages aimed at supporting overall wellness after social occasions. unbuzzd is a refreshing, science-backed beverage that helps people feel more refreshed and alert after drinking. This offering will help us raise the necessary capital to support direct-to-consumer, distributor, and retail expansion plans.' Mr. Duffy has over twenty years of leadership experience in the beverage industry, including as former VP of Marketing Assets and VP of National Sales at Coca-Cola. Gerry David, Board Co-Chair and former CEO of Celsius Holdings with their bestselling energy drink Celsius Energy, added, "Together with our partners MZ Digital, a global leader in online marketing, and Dealmaker, a leading online platform for raising capital, we are excited to launch this offering to build our company and sales momentum, and position Unbuzzd for a future initial public offering." About Quantum BioPharma Ltd. Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ('Lucid'), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Unbuzzd Wellness Inc. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. For more information on Quantum BioPharma, please visit About Unbuzzd Wellness Inc. Unbuzzd Wellness inc., a non-trading but fully reporting public issuer, stands as a pioneering force in the wellness and recovery supplement landscape. unbuzzd has been developed by a world-class R&D team in pharmacology and medicine, with a commitment to innovation and quality. A proprietary blend of vitamins, minerals, and herbs, unbuzzd helps your body process alcohol faster, restore mental alertness, and improve cognition so you can drink responsibly and drink refreshingly. unbuzzd appeals to a broad target audience of alcohol consumers who want to have a good time, be in control, and still feel great the next day. Scientifically backed by a recently completed double-blind, randomized, placebo-controlled crossover design clinical trial, unbuzzd dramatically accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration ("BAC"), restores mental clarity, and reduces the symptoms of intoxication, impairment and hangover. Key findings from the clinical trial include: Accelerated Alcohol Metabolism: unbuzzd dramatically and rapidly reduced blood alcohol concentration in study participants. The rate at which BAC was lowered was, on average for most participants, more than 40 percent faster within 30 minutes of consuming unbuzzd compared to control subjects. Rapid Improvements in Alertness: Study participants reported statistically significant improvement in alertness as soon as 30 minutes after consuming unbuzzd. Participants felt more alert and made fewer cognitive errors within 30 minutes of consuming unbuzzd, significantly outperforming placebo results. Rapid Improvements in Physiologic Changes due to Intoxication: unbuzzd lessened the elevation in heart rate and the drop in blood pressure that often accompanies alcohol intoxication, stabilizing both. This result was statistically significant. Reduced Perceived Impairment and Mental Fatigue: unbuzzd helped alleviate perceived impairment and mental fatigue caused by alcohol intoxication. Hangover Relief: Participants in this study noted a statistically significant reduction in hangover symptoms. This included reduced cognitive and physical impairment, and reduced headache compared to placebo results, at both four hours (67 percent reduction in headache severity) and eight hours after consuming unbuzzd. No Side Effects: unbuzzd was well-tolerated by all study participants, with no reported adverse side effects. The full press release of the clinical trial can be found here. unbuzzd ready-to-mix powder sticks are available in 3-pack and 18-pack formats at unbuzzdTM is a registered trademark of Unbuzzd Wellness Inc. Individual results may vary. unbuzzd is a dietary supplement. Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE. For more information on Unbuzzd Wellness Inc. please visit 18-pack, and 3-pack formats of the unbuzzd ready-to-mix powder sticks Forward-Looking Information Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such. Forward-looking information in this press release are based on certain assumptions and expected future events. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at and on the EDGAR section of the United States Securities and Exchange Commission's website at for a more complete discussion of such risk factors and their potential effects. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law. Contacts: Quantum BioPharma Saeed, Founder, CEO and Executive Co-Chairman of the BoardEmail: Zsaeed@ (833) 571-1811 Investor RelationsInvestor Relations: IR@ Inquiries: info@ A photo accompanying this announcement is available at in to access your portfolio
